纵横研报
Ticker Detail

603127.SHG

¥50.62+10.00% 昭衍新药 Diagnostics & Research
00Reports China 医疗健康
Joinn Laboratories(China)Co
医疗健康 · 诊断与研究

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies. Its Clinical Trial and Related Services segment provide clinical contract research organization services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment engages in the design, production, breeding, and sale of research models, including non-human primates and rodents. The company also offers cell-based assay (CBA) services. In addition, it offers drug quality research and testing services for protein drugs, vaccines, gene and cell therapy products, and provides customized solutions for early-stage drug discovery, screening, and mechanism research. Joinn Laboratories(China)Co.,Ltd. was incorporated in 1995 and is headquartered in Beijing, China.

MARKET 市值 32.39B CNY PE 64.5x Fwd 36.1x 52W ¥24.46 – ¥45.95 EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG 营收 YoY 10.0% ROE 5.9% 营业利润率 -9.7% 净利润率 29.4%
ANALYST 股息率 0.31%

暂无相关研报

数据库中已收录该标的的基本面数据,可发起一份定制研报。

CUSTOM RESEARCH · 定制研报 没找到完全契合的标的?让我们替你做一份。 告诉我们你关心的标的与偏好,1 个工作日内在站内上线。 开始定制